🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

RecruitingPhase 3Ages 8 Years - 85 YearsAllAnnexon, Inc.
NCT07020819 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Key Inclusion Criteria: * Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS. * Onset of GBS-related weakness ≤10 days before start of infusion on Day 1 * GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1. Key Exclusion Criteria: * Previous or planned treatment with either plasma exchange or IV immunoglobulin within 90 days of Day 1. * Diagnosis of any form of GBS that does not involve weakness of the extremities. Other protocol-defined criteria may apply.
💊

What it tests

  • Tanruprubart
📍

Where

30 sites
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (Dignity Health)
Phoenix, United States
HonorHealth Bob Bové Neuroscience Institute
Scottsdale, United States
Profound Research LLC
Carlsbad, United States
Loma Linda
Loma Linda, United States
Children's Hospital of Orange County
Orange, United States
University of California Irvine
Orange, United States
Stanford University
Palo Alto, United States
University of Colorado Hospital
Aurora, United States

…and 22 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy